SKLB023 Blocks Joint Inflammation and Cartilage Destruction in Arthritis Models via Suppression of Nuclear Factor-Kappa B Activation in Macrophage

Xie, Caifeng; Ma, Liang; Liu, Juan; Li, Xiuxia; Pei, Heying; Xiang, Mingli; Chen, Lijuan
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Rheumatoid arthritis (RA) is the most common arthritis and is mainly characterized by symmetric polyarticular joint disorders. Our previous study demonstrated a novel small molecule compound (Z)-N-(3-Chlorophenyl)-2-(4-((2,4-dioxothiazolidin-5-ylidene) methyl) phenoxy) acet-amide (SKLB023) showed potently anti-arthritic effects in a rat arthritis model, however, the underlying mechanisms for this are largely unknown. Both NF-κB and macrophages were reported to play important roles in the pathologic processes of RA. The purposes of this study were to indicate whether NF-κB and macrophages contributed to anti-arthritic effects of SKLB023 in two experimental arthritis models. Our results showed that SKLB023 could significantly improve joint inflammation and cartilage destruction both in adjuvant induced arthritis (AIA) and collagen-induced arthritis (CIA) models. We further found that the binding activation of NF-κB to DNA in joint tissues and RAW264.7 macrophages were suppressed by SKLB023. SKLB023 also inhibited the NF-κB activity in peritoneal macrophages by luciferase assay. Furthermore, the number of macrophages in synovial tissues was decreased after the treatment of different doses of SKLB023. The levels of TNF-α, IL-1β, and IL-6 in plasma, and the levels of TNF-α, NO, and IL-1β in peritoneal macrophages were down-regulated by SKLB023. Finally, SKLB023 attenuated the expression of iNOS and COX-2 in vivo and suppressed the phosphorylations of components of the mitogen-activated protein kinases (MAPKs). These observations identify a novel function for SKLB023 as an inhibitor of NF-κB in macrophages of RA, highlighting that SKLB023 was a potential therapeutic strategy for RA.


Related Articles

  • Histone Deacetylase Inhibitors: New Hope for Rheumatoid Arthritis? Choo, Q. Y.; Ho, P. C.; Lin, H. S. // Current Pharmaceutical Design;Mar2008, Vol. 14 Issue 8, p803 

    Histone deacetylase (HDAC) inhibitors are a new family of anti-cancer agents currently undergoing clinical investigations for various oncology indications. Their anti-inflammatory activities had been well documented and they appear to be potential therapeutic strategies for various inflammatory...

  • Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-{kappa}B pathway. L. Pattacini; B. Casali; L. Boiardi; N. Pipitone; L. Albertazzi; C. Salvarani // Rheumatology;Jul2007, Vol. 46 Issue 8, p1252 

    Objective. To evaluate the effects of angiotensin II (Ang II) treatment on apoptosis of fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Methods. AT1 receptor expression was detected by western blotting and flow cytometry. Apoptosis...

  • Suppression of Erosive Arthritis by NF-?B Inhibitors. Kubota, Tetsuo; Umezawa, Kazuo // Current Rheumatology Reviews;2011, Vol. 7 Issue 4, p275 

    Excess activation of NF-kappa B is often involved in inflammation and cancer progression. We have developed a specific NF-kappa B inhibitor dehydroxyepoxyquinomicin (DHMEQ). It binds to the specific cysteine residue of Rel family proteins. DHMEQ inhibited cytokine secretions and...

  • Nuclear factor κB: a potential therapeutic target in atherosclerosis and thrombosis Monaco, Claudia; Paleolog, Ewa // Cardiovascular Research;Mar2004, Vol. 61 Issue 4, p671 

    Cardiovascular diseases are the leading cause of morbidity and mortality in Western countries. Atherosclerosis, the background for many cardiovascular diseases, is characterized by the accumulation of lipid and fibrotic entities in large arteries and bears many similarities with chronic...

  • NF-kappaB inducing kinase (NIK) is a key regulator of inflammation-induced angiogenesis. Noort, Ae-Ri; van Zoest, Katinka P. M.; Koolwjk, Pieter; Tak, Paul-Peter; Tas, Sander W. // Journal of Translational Medicine;2012, Vol. 10 Issue Suppl 3, p1 

    The article presents a study which examines the role of non-canonical nuclear factor-kappaB (NF-kB) signaling in pathological angiogenesis in rheumatoid arthritis (RA). The study evaluates the expression of kinase (NIK) and chemokine CXCL12 in RA synovial tissue (ST) using immunofluorescence...

  • NF-κ B and Rheumatic Diseases. Okamoto, Takashi // Endocrine, Metabolic & Immune Disorders - Drug Targets;Dec2006, Vol. 6 Issue 4, p359 

    NF-κB is an inducible transcription factor that is controlled by the signal activation cascades. NF-κB controls a number of genes involved in immuno-inflammatory responses, cell cycle progression, inhibition of apoptosis, and cell adhesion, thus promoting chronic inflammatory responses. In...

  • The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis. Skoumal, Martin; Haberhauer, Günther; Kolarz, Gernot; Hawa, Gerhard; Woloszczuk, Wolfgang; Klingler, Anton; Varga, Franz; Klaushofer, Klaus // Rheumatology International;May2008, Vol. 28 Issue 7, p637 

    Osteoprotegerin (OPG) and soluble receptor activator of NF-kappa B ligand (sRANKL) together regulate the bone metabolism among other cytokines, whereby cathepsin K has a potent collagen-degrading activity. An imbalance of this system may be partly responsible for the skeletal complications of...

  • Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis. Ellabban, Abdou; Kamel, Shereen; Ahmed, Shimaa; Osman, Ashraf // Rheumatology International;Jun2012, Vol. 32 Issue 6, p1589 

    To assess the levels of receptor activator of NF-κB ligand (RANKL) in serum and synovial fluid (SF) of patients with rheumatoid arthritis (RA) and osteoarthritis (OA) and to correlate its levels with disease activity and severity. Serum and SF levels of RANKL were measured in 24 patients with...

  • Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Skoumal, M.; Kolarz, G.; Haberhauer, G.; Woloszczuk, W.; Hawa, G.; Klingler, A. // Rheumatology International;Nov2005, Vol. 26 Issue 1, p63 

    We examined OPG and soluble RANKL in the serum (sOPG, sRANKL) and synovial fluid (synOPG, synRANKL) in patients with rheumatoid arthritis (RA) and osteoarthritis (OA). OPG and RANKL were measured in 85 patients (44 with RA, 41 patients with OA) in serum and synovial fluid as well. For measuring...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics